CLINICAL TRIALS PROFILE FOR OXYTROL FOR WOMEN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for OXYTROL FOR WOMEN
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT04534491 ↗ | Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream. | Completed | Bayer | Phase 3 | 2010-05-25 | With this study researchers want to gather information about the consumer use behavior of Oxytrol in a simulated setting in which the medicine is sold directly to a consumer without a prescription from a healthcare professional. An area of focus was on the potential benefits of an over-the-counter status for Oxytrol and on the ongoing use behavior of the consumers. Oxytrol is a thin, flexible, clear patch that is indicated for the treatment of overactive bladder a disease characterized by a collection of symptoms, including urinary frequency, urgency, and urge incontinence. The adhesive patch is placed on the skin to deliver Oxytrol through the skin into the bloodstream. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for OXYTROL FOR WOMEN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00224016 ↗ | Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition | Completed | Watson Pharmaceuticals | Phase 4 | 2004-12-01 | This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder. |
| NCT00224029 ↗ | A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition | Completed | Watson Pharmaceuticals | Phase 4 | 2004-12-01 | This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury. |
| NCT00224146 ↗ | Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder | Completed | Watson Pharmaceuticals | Phase 4 | 2004-05-01 | This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r) |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OXYTROL FOR WOMEN
Condition Name
Clinical Trial Locations for OXYTROL FOR WOMEN
Trials by Country
Clinical Trial Progress for OXYTROL FOR WOMEN
Clinical Trial Phase
Clinical Trial Sponsors for OXYTROL FOR WOMEN
Sponsor Name
| Sponsor Name for OXYTROL FOR WOMEN | |
| Sponsor | Trials |
| Watson Pharmaceuticals | 3 |
| Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 1 |
| Ottawa General hospital, Ottawa University, Ottawa, Ontario, Canada | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
